Lupin unveils Glucagon for Injection for severe hypoglycemia in patients with diabetes mellitus in US
Mumbai: Global pharma major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States.
Glucagon for Injection USP, 1mg/vial packaged in an emergency kit is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company.
The launch follows the approval from the United States Food and Drug Administration (USFDA) of Lupin's Abbreviated New Drug Applications (ANDAs) for Glucagon for the product in June.
Read also: Lupin wins USFDA nods for Liraglutide, Glucagon Injectable Products
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the U.S. (IQVIA MAT June 2025).
In July, Lupin also launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States, following United States Food and Drug Administration (USFDA) approval last year. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. It is also indicated for the treatment of post-operative inflammation following ocular surgery.
Read also: Lupin rolls out Loteprednol Etabonate Ophthalmic Suspension, 0.5% in US
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.
Read also: Lupin, Zentiva ink pact to commercialize arthritis drug Certolizumab Pegol
